ONLINE FIRST (FREE ACCESS) LATEST ARTICLES ICM Rapid Practice GuidelinesERC-ESICM guidelines on temperature control after cardiac arrest in adultsSandroni C. et al. OriginalsMental health symptoms in family members of COVID-19 ICU survivors 3 and 12 months after ICU admission: a multicentre prospective cohort studyHeesakkers H. et al.Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in...

ORIGINAL ARTICLEFREE PREVIEW 24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk Yuan Ma, Feng J. He, Qi Sun, et al N Engl J Med 2022; 386:252-263DOI: 10.1056/NEJMoa2109794 Abstract BACKGROUND The relation between sodium intake and cardiovascular disease remains controversial, owing in part to inaccurate assessment of sodium intake. Assessing 24-hour urinary excretion over a period of multiple days is considered to be an accurate metho...

ONLINE FIRST (FREE ACCESS) LATEST ARTICLES OriginalUndocumented migrants in French intensive care units in 2011–2018: retrospective nationwide studyHraiech S. et al. Systematic Review Effect of prone positioning on survival in adult patients receiving venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysisPapazian L. et al. EditorialTowards evidence-based staffing: the promise a...

ARTICLES|ONLINE FIRST Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial E Wesley Ely, Athimalaipet V Ramanan, Cynthia E Kartman, et al Lancet Respir Med Published:February 03, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00006-6 Summary Background ...

ORIGINAL ARTICLEFREE PREVIEW SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection Paul Feuerstadt, Thomas J. Louie, Bret Lashner, et al N Engl J Med 2022; 386:220-229DOI: 10.1056/NEJMoa2106516 Abstract BACKGROUND Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria...

ARTICLES| VOLUME 22, ISSUE 2, P196-208, FEBRUARY 01, 2022 Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial ShengLi Xia, YunTao Zhang, YanXia Wang, et al Lancet Infect Dis 2022; 22: 196-208 Summary Background Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a k...

ORIGINAL ARTICLEFREE PREVIEW Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants Laura L. Hammitt, Ron Dagan, Yuan Yuan, et al N Engl J Med 2022; 386:837-846DOI: 10.1056/NEJMoa2110275 Abstract BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and s...

ORIGINAL ARTICLE Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines Nick Andrews, Elise Tessier, Julia Stowe, et al N Engl J Med January 12, 2022DOI: 10.1056/NEJMoa2115481 Abstract BACKGROUND Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since December 2020 in the United Kingdom. Real-world data have shown the vaccines ...

ARTICLES| VOLUME 22, ISSUE 2, P209-221, FEBRUARY 01, 2022 Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, et al Lancet Infect Dis 2022; 22: 209-221 Summary Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversia...

ORIGINAL ARTICLEFREE PREVIEW High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality P.J. Devereaux, Andre Lamy, Matthew T.V. Chan, et al N Engl J Med 2022; 386:827-836DOI: 10.1056/NEJMoa2000803 Abstract BACKGROUND Consensus recommendations regarding the threshold levels of cardiac troponin elevations for the definition of perioperative myocardial infarction and clinically important periprocedural myocardial injury in patients undergo...